Research and Markets - Fluorescent Proteins are Fast Providing Novel Insights into Compound-Induced Responses In Drug Discovery

Research and Markets has announced the addition of Fluorescent Proteins: Technologies, Applications, and Opportunities for Drug Discovery to their offering.

(PRWEB) October 25, 2004 -- Research and Markets (http://www.researchandmarkets.com/reports/c7996) has announced the addition of Fluorescent Proteins: Technologies, Applications, and Opportunities for Drug Discovery to their offering.

Fluorescent proteins are fast providing novel insights into compound-induced responses in drug discovery. This is taking place from two key vantage points, namely, in real time and in living systems. With non-invasive, non-destructive properties along with the benefit of being genetically-encoded, fluorescent proteins are attractive candidates for tagging a promoter, gene, protein or drug target of interest, in drug discovery based on live-cell analysis.

One major factor contributing to the current applicability of fluorescent proteins is the rich knowledge base available from the cloning, characterization and optimization of the first fluorescent protein cloned - green-fluorescent protein (GFP). Such developments in GFP technology have laid a sound base for future developments associated with fluorescent proteins. Fluorescent proteins, as a wider resource, first became available in 1999 when 'GFP-like' clones were obtained from an unexpected source - non-luminous Indo-Pacific reef corals. This considerably expanded the 'search area' for 'GFP-like' fluorescent proteins, and as such, now over 100 fluorescent proteins have been cloned. In terms of light emission, available fluorescent proteins now collectively span the entire visible color spectrum. These developments provide the assay developer or drug screener with a myriad of fluorescent proteins as assay or screening tools, each with its own shades, tones and hues along with its own unique physical, chemical and biological characteristics.

This Report describes fluorescent proteins, associated technology and applications, the market for fluorescent proteins and future perspectives on fluorescent proteins. In addition, the intellectual property landscape in this area is summarized, companies invested in fluorescent protein drug discovery are profiled, and key industry players are interviewed.

Company Profiles Include:
-   Amersham Biosciences
-   AntiCancer
-   BD Biosciences Clontech
-   BioImage
-   Bio-Rad Laboratories
-   Cellomics
-   Evotec OAI
-   Evrogen
-   Genetix
-   Gentronix
-   Guava Technologies
-   Invitrogen
-   Norak Biosciences
-   Promega
-   Qbiogene
-   Stratagene
-   Universal Imaging Corporation
-   Zygogen

This Report will benefit professionals involved in the pharmaceutical and biotechnology industries, including Group Leaders, Senior Scientists, VPs of Business Development, VPs of Marketing, Licensing professionals, and other major decision-makers.

In addition, to professionals in pharmaceutical R&D and drug screening, molecular reagents and tool suppliers, biotechnology companies including those utilizing a cell-based approach or in genomics and proteomics. Also companies supplying fluorescence-based instrumentation and fluorescent protein suppliers.

Contents Include
- Introduction
- Fluorescent Proteins
- Characteristics of Fluorescent Proteins
- Commercialization and Applications of Fluorescent Proteins
- Fluorescent Protein Technology
- Current Market Activity and Fluorescent Protein Technology
- Future Implications of Fluorescent Protein Technology
- Company Profiles
- Interviews with Industry Experts

For more information visit http://www.researchandmarkets.com/reports/c7996

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

###